NASDAQ:AFMD - Affimed Stock Price, Price Target & More

$2.04 -0.01 (-0.49 %)

(As of 04/23/2018 01:12 PM ET)

Previous Close$2.05

Today's Range$2.00 - $2.10

52-Week Range$1.15 - $2.85

Volume142,667 shs

Average Volume717,396 shs

Market Capitalization$127.90 million

P/E Ratio-2.65

Dividend YieldN/A

Beta2.29

About Affimed (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:AFMD

CUSIPN/A

Webwww.affimed.com

Phone49-62-2165-3070

Debt

Debt-to-Equity Ratio0.13%

Current Ratio5.61%

Quick Ratio5.58%

Price-To-Earnings

Trailing P/E Ratio-2.65

Forward P/E Ratio-3.04

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.27 million

Price / Sales56.07

Cash FlowN/A

Price / CashN/A

Book Value$0.80 per share

Price / Book2.55

Profitability

EPS (Most Recent Fiscal Year)($0.78)

Net Income$-34,160,000.00

Net Margins-1,493.69%

Return on Equity-80.04%

Return on Assets-61.56%

Miscellaneous

Employees53

Outstanding Shares62,390,000

How to Become a New Pot Stock Millionaire

Affimed (NASDAQ:AFMD) Frequently Asked Questions

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its earnings results on Tuesday, March, 20th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The biopharmaceutical company earned $0.75 million during the quarter, compared to the consensus estimate of $0.56 million. Affimed had a negative net margin of 1,493.69% and a negative return on equity of 80.04%. View Affimed's Earnings History.

When is Affimed's next earnings date?

Affimed is scheduled to release their next quarterly earnings announcement on Wednesday, May, 16th 2018. View Earnings Estimates for Affimed.

What price target have analysts set for AFMD?

3 brokers have issued 12-month price objectives for Affimed's shares. Their forecasts range from $2.50 to $10.00. On average, they expect Affimed's share price to reach $6.50 in the next year. View Analyst Ratings for Affimed.

Who are some of Affimed's key competitors?

Some companies that are related to Affimed include Athersys (ATHX), Bellicum Pharmaceuticals (BLCM), ArQule (ARQL), resTORbio (TORC), Ovid Therapeutics (OVID), Chimerix (CMRX), Ocular Therapeutix (OCUL), Viking Therapeutics (VKTX), Vital Therapies (VTL), Neos Therapeutics (NEOS), Synlogic (SYBX), Melinta Therapeutics (MLNT), Aratana Therapeutics (PETX), Molecular Templates (MTEM), Ardelyx (ARDX), MannKind (MNKD), CTI BioPharma (CTIC) and Recro Pharma (REPH).

Who are Affimed's key executives?

Affimed's management team includes the folowing people:

Dr. Adi Hoess M.D., Ph.D., CEO, MD & Member of Management Board (Age 56)
Dr. Florian H. M. Fischer MBA (Dipl.-Kfm.), Ph.D., MD, CFO & Member of Management Board (Age 50)
Prof. Melvyn Little Ph.D., Founder and Consultant
Dr. Wolfgang Fischer, Chief Operating Officer and Interim CMO
Dr. Martin Treder, Chief Scientific Officer (Age 48)

Has Affimed been receiving favorable news coverage?

Media coverage about AFMD stock has trended positive on Monday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Affimed earned a coverage optimism score of 0.25 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 44.99 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Affimed's major shareholders?

Affimed's stock is owned by many different of institutional and retail investors. Top institutional investors include INTEGRATED CORE STRATEGIES (US) LLC (5.20%). View Institutional Ownership Trends for Affimed.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $2.04.

How big of a company is Affimed?

Affimed has a market capitalization of $127.90 million and generates $2.27 million in revenue each year. The biopharmaceutical company earns $-34,160,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Affimed employs 53 workers across the globe.

How can I contact Affimed?

Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2165-3070 or via email at [email protected]

MarketBeat Community Rating for Affimed (AFMD)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		136 (Vote Outperform)
Underperform Votes:		161 (Vote Underperform)
Total Votes:		297

MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Affimed (NASDAQ:AFMD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Affimed in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 218.63%. The high price target for AFMD is $10.00 and the low price target for AFMD is $2.50. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.33	2.33	2.33	2.50
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$6.50	$6.50	$6.50	$5.3750
Price Target Upside:	218.63% upside	209.52% upside	209.52% upside	150.00% upside

Affimed (NASDAQ:AFMD) Consensus Price Target History

Price Target History for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/24/2017	Oppenheimer	Reiterated Rating	Hold		Low
7/27/2017	Jefferies Group	Reiterated Rating	Hold	$2.50	Low
7/13/2017	SunTrust Banks	Initiated Coverage	Buy -> Buy	$7.00	High
11/3/2016	Leerink Swann	Reiterated Rating	Hold	$2.00	N/A
5/18/2016	Wells Fargo	Reiterated Rating	Buy		N/A

(Data available from 4/23/2016 forward)

Affimed (NASDAQ:AFMD) Earnings History and Estimates Chart

Earnings by Quarter for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.65)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.15)	($0.15)	($0.15)
Q2 2018	1	($0.16)	($0.16)	($0.16)
Q3 2018	1	($0.17)	($0.17)	($0.17)
Q4 2018	2	($0.17)	($0.17)	($0.17)

Affimed (NASDAQ AFMD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/16/2018
3/20/2018	Q4 2017	($0.16)	($0.16)	$0.56 million	$0.75 million	View	Listen
11/7/2017	Q3 2017	($0.21)	($0.21)	$0.97 million	$0.55 million	View	N/A
8/3/2017	6/30/2017	($0.22)	($0.20)	$1.31 million	$0.51 million	View	Listen
5/17/2017	3/31/2017	($0.24)	($0.21)	$1.73 million	$1.94 million	View	N/A
3/30/2017	12/31/2016	($0.31)	($0.17)	$1.20 million	$1.37 million	View	N/A
11/2/2016	Q316	($0.26)	($0.31)	$2.65 million	$0.94 million	View	N/A
8/10/2016	Q216	($0.22)	($0.24)	$2.10 million	$2.07 million	View	Listen
5/18/2016	Q116	($0.15)	($0.25)	$1.88 million	$1.90 million	View	Listen
3/30/2016	Q415	($0.18)	($0.19)	$1.71 million	$1.66 million	View	Listen
11/10/2015	Q315	($0.25)	($0.27)	$1.87 million	$1.20 million	View	Listen
8/4/2015	Q215	($0.14)	($0.21)	$2.56 million	$2.21 million	View	N/A
5/21/2015	Q115	($0.1350)	($0.0670)	$4.75 million	$2.82 million	View	Listen
3/25/2015	Q414	($0.39)	($0.24)	$0.89 million	$0.09 million	View	N/A
11/18/2014	Q314	($0.33)	$2.69	$0.89 million	$2.35 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Affimed (NASDAQ:AFMD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Affimed (NASDAQ AFMD) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 27.86%

Insider Trading History for Affimed (NASDAQ:AFMD)

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ AFMD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Affimed (NASDAQ AFMD) News Headlines

Source:

Date	Headline
	Active-Investors: Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen's BAY 1905254 Efficacy in Cancer Immunotherapy www.finanznachrichten.de - April 19 at 9:13 AM
	Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy finance.yahoo.com - April 16 at 4:34 PM
	Affimed (AFMD) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 12 at 4:31 PM
	Affimed (AFMD) Upgraded to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 4 at 4:42 PM
	Zacks Investment Research Upgrades Affimed (AFMD) to Buy www.americanbankingnews.com - March 29 at 4:10 PM
	Zacks Investment Research Lowers Affimed (AFMD) to Hold www.americanbankingnews.com - March 28 at 4:25 PM
	Q4 2018 Earnings Forecast for Affimed NV Issued By Jefferies Group (AFMD) www.americanbankingnews.com - March 26 at 1:39 AM
	Affimed (AFMD) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - March 23 at 4:34 PM
	SunTrust Banks Equities Analysts Boost Earnings Estimates for Affimed NV (AFMD) www.americanbankingnews.com - March 23 at 7:50 AM
	Edited Transcript of AFMD earnings conference call or presentation 20-Mar-18 12:30pm GMT finance.yahoo.com - March 21 at 10:21 AM
	Affimed (AFMD) Issues Earnings Results www.americanbankingnews.com - March 21 at 8:59 AM
	Affimed N.V. to Host Earnings Call finance.yahoo.com - March 20 at 9:29 AM
	Has Affimed NV. (NASDAQ:AFMD) Improved Earnings Growth In Recent Times? finance.yahoo.com - March 20 at 9:29 AM
	Affimed Reports Financial Results for Fourth Quarter and Year End 2017 finance.yahoo.com - March 20 at 9:29 AM
	Affimed Appoints Dr. Leila Alland as Chief Medical Officer finance.yahoo.com - March 19 at 9:27 AM
	Why Earnings Season Could Be Great for Affimed (AFMD) finance.yahoo.com - March 19 at 9:27 AM
	Affimed (AFMD) Set to Announce Earnings on Tuesday www.americanbankingnews.com - March 14 at 12:21 PM
	Affimed NV. (NASDAQ:AFMD): When Will It Breakeven? finance.yahoo.com - March 12 at 5:40 PM
	$1.15 Million in Sales Expected for Affimed NV (AFMD) This Quarter www.americanbankingnews.com - March 9 at 2:04 AM
	Affimed NV (AFMD) Expected to Announce Earnings of -$0.17 Per Share www.americanbankingnews.com - March 7 at 9:14 PM
	Critical Comparison: Affimed (AFMD) & Molecular Templates (MTEM) www.americanbankingnews.com - March 7 at 3:10 AM
	Breaking Down Affimed NV.’s (NASDAQ:AFMD) Ownership Structure finance.yahoo.com - February 22 at 4:57 PM
	Brokerages Anticipate Affimed NV (AFMD) Will Post Quarterly Sales of $1.15 Million www.americanbankingnews.com - February 21 at 12:21 PM
	Is Affimed NV.’s (NASDAQ:AFMD) CEO Pay Justified? finance.yahoo.com - February 15 at 4:42 PM
	Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares finance.yahoo.com - February 15 at 4:42 PM
	Affimed Announces Proposed Public Offering of Common Stock finance.yahoo.com - February 12 at 4:23 PM
	Zacks: Brokerages Anticipate Affimed NV (AFMD) Will Announce Quarterly Sales of $1.15 Million www.americanbankingnews.com - February 4 at 11:40 AM
	Equities Analysts Issue Forecasts for Affimed NV's FY2022 Earnings (AFMD) www.americanbankingnews.com - February 2 at 4:32 PM
	Affimed NV (AFMD) Expected to Post Earnings of -$0.17 Per Share www.americanbankingnews.com - February 2 at 5:16 AM
	Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas finance.yahoo.com - February 1 at 9:21 AM
	Should You Have Affimed NV’s (NASDAQ:AFMD) In Your Portfolio? finance.yahoo.com - January 29 at 4:18 PM
	Affimed NV (AFMD) Expected to Announce Quarterly Sales of $1.15 Million www.americanbankingnews.com - January 18 at 10:30 AM
	Affimed NV (NASDAQ:AFMD): Immense Growth Potential? finance.yahoo.com - January 10 at 11:21 AM
	Affimed N.V. (AFMD) Expected to Announce Quarterly Sales of $1.15 Million www.americanbankingnews.com - December 15 at 2:56 PM
	Did Affimed NV’s (NASDAQ:AFMD) Recent Earnings Growth Beat The Trend? finance.yahoo.com - December 15 at 11:51 AM
	Affirmed, Data Due in December, Potential Catalysts, Clinical Highlights finance.yahoo.com - November 28 at 9:25 AM
	Analysts Expect Affimed N.V. (AFMD) Will Post Quarterly Sales of $970,000.00 www.americanbankingnews.com - November 27 at 6:16 PM
	Affimed's (AFMD) Hold Rating Reaffirmed at Oppenheimer Holdings, Inc. www.americanbankingnews.com - November 27 at 1:14 PM
	Analysts Anticipate Affimed N.V. (AFMD) to Announce -$0.18 Earnings Per Share www.americanbankingnews.com - November 25 at 11:34 AM
	FY2018 EPS Estimates for Affimed N.V. (AFMD) Increased by Analyst www.americanbankingnews.com - November 10 at 5:40 PM
	What Does Affimed NV’s (AFMD) Share Price Indicate? finance.yahoo.com - November 10 at 4:10 PM
	Affimed N.V. to Post Q1 2018 Earnings of ($0.20) Per Share, SunTrust Banks Forecasts (AFMD) www.americanbankingnews.com - November 10 at 11:06 AM
	Leerink Swann Comments on Affimed N.V.'s FY2017 Earnings (AFMD) www.americanbankingnews.com - November 10 at 8:36 AM
	Affimed NV :AFMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 finance.yahoo.com - November 8 at 5:46 PM
	Affimed N.V. (AFMD) Expected to Post Quarterly Sales of $970,000.00 www.americanbankingnews.com - November 8 at 6:32 AM
	Edited Transcript of AFMD earnings conference call or presentation 7-Nov-17 1:30pm GMT finance.yahoo.com - November 7 at 10:12 PM
	Affimed Reports Financial Results for Third Quarter 2017 finance.yahoo.com - November 7 at 5:08 PM
	Affimed N.V. (AFMD) Releases Earnings Results, Beats Estimates By $0.03 EPS www.americanbankingnews.com - November 7 at 1:58 PM
	Brokerages Anticipate Affimed N.V. (AFMD) to Announce -$0.21 Earnings Per Share www.americanbankingnews.com - November 6 at 3:08 PM
	Affimed to Present Clinical and Preclinical Data on Immune Cell Engagers at ASH finance.yahoo.com - November 1 at 3:58 PM

Affimed (NASDAQ:AFMD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Affimed (NASDAQ:AFMD) Income Statement, Balance Sheet and Cash Flow Statement

Affimed (NASDAQ AFMD) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff